RightFit Trial Directory

Lung Cancer clinical trials in Chicago, IL

47 recruiting lung cancer studies with a site in Chicago, IL.

All trials in Chicago, IL · All Lung Cancer trials

RecruitingPhase 3NCT03394365

A Phase 3 Study of Tabelecleucel for Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease After Failure With Rituximab or Rituximab and Chemotherapy

Sponsor: Pierre Fabre Medicament

Chicago, IL · Maywood, IL · +37 more sites

RecruitingPhase 3NCT04267848

Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])

Sponsor: National Cancer Institute (NCI)

Alton, IL · Aurora, IL · Barrington, IL · +1147 more sites

RecruitingPhase 3NCT06498635

Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial

Sponsor: National Cancer Institute (NCI)

Chicago, IL · DeKalb, IL · Geneva, IL · +278 more sites

RecruitingPhase 1NCT06465069

A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors

Sponsor: Eli Lilly and Company

Chicago, IL · +22 more sites

RecruitingPhase 3NCT06623422

A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)

Sponsor: Merck Sharp & Dohme LLC

Chicago, IL · Peoria, IL · +52 more sites

RecruitingPhase 1 / Phase 2NCT06810544

Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss

Sponsor: Tango Therapeutics, Inc.

Chicago, IL · +14 more sites

RecruitingPhase 1NCT06545331

Study of XB010 in Subjects With Solid Tumors

Sponsor: Exelixis

Chicago, IL · +15 more sites

RecruitingPhase 3NCT07128199

A Study to Assess Zipalertinib Versus Placebo in Participants With Early Stage NSCLC With Uncommon EGFR Mutations, Following Complete Tumor Resection

Sponsor: Taiho Oncology, Inc.

Chicago, IL · +29 more sites

RecruitingPhase 3NCT07144280

A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)

Sponsor: Pfizer

Arlington Heights, IL · Bloomington, IL · Chicago, IL · +238 more sites

RecruitingPhase 2NCT06031688

Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)

Sponsor: SWOG Cancer Research Network

Bloomington, IL · Canton, IL · Carthage, IL · +275 more sites

RecruitingPhase 2 / Phase 3NCT07100080

Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)

Sponsor: Bristol-Myers Squibb

Chicago, IL · +27 more sites

RecruitingPhase 3NCT07222566

Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Sponsor: Pfizer

Arlington Heights, IL · Bloomington, IL · Chicago, IL · +223 more sites

RecruitingPhase 3NCT06119581

A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer

Sponsor: Eli Lilly and Company

Chicago, IL · Springfield, IL · +84 more sites

RecruitingPhase 1 / Phase 2NCT06780137

A Study to Evaluate the Safety and Efficacy of Gocatamig (MK-6070) and Ifinatamab Deruxtecan (I-DXd) in Participants With Relapsed/Refractory Extensive-Stage Small Cell Lung Cancer (MK-6070-002)

Sponsor: Merck Sharp & Dohme LLC

Chicago, IL · +8 more sites

RecruitingPhase 1NCT07454642

AVA6103 in Subjects With Locally Advanced or Metastatic Selected Solid Tumors

Sponsor: Avacta Life Sciences Ltd

Chicago, IL · +6 more sites

RecruitingPhase 2NCT07293247

A Study of Targeted Post-Surgery Radiation Therapy for Non-Small Cell Lung Cancer With Remaining Lymph Node Cancer After Treatment

Sponsor: Alliance for Clinical Trials in Oncology

Bloomington, IL · Canton, IL · +108 more sites

RecruitingPhase 2NCT06172478

A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors

Sponsor: Daiichi Sankyo

Chicago, IL · +12 more sites

RecruitingPhase 1 / Phase 2NCT06362252

A Study of I-DXd in Combination With Atezolizumab With or Without Carboplatin as First-Line Induction or Maintenance in Subjects With Extensive Stage-Small Cell Lung Cancer (IDeate-Lung03)

Sponsor: Daiichi Sankyo

Chicago, IL · +25 more sites

RecruitingPhase 3NCT07361497

A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)

Sponsor: Bristol-Myers Squibb

Chicago, IL · Evanston, IL · Peoria, IL · +35 more sites

RecruitingPhase 1NCT06218914

Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid Tumors

Sponsor: AstraZeneca

Chicago, IL · +17 more sites

RecruitingPhase 1NCT06858813

A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused ABBV-324 in Adult Participants With Hepatocellular Cancer (HCC) or Squamous-Cell Non-Small Cell Lung Cancer (LUSC)

Sponsor: AbbVie

Chicago, IL · +9 more sites

RecruitingPhase 1NCT05983432

Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors

Sponsor: SystImmune Inc.

Chicago, IL · +21 more sites

RecruitingPhase 3NCT06767514

Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1

Sponsor: Summit Therapeutics

Carterville, IL · Chicago, IL · +94 more sites

RecruitingPhase 2NCT07002034

RE104 Safety and Efficacy Study in Adjustment Disorder in Cancer and Other Medical Illnesses

Sponsor: Reunion Neuroscience Inc

Chicago, IL · +30 more sites

RecruitingPhase 1NCT05245500

Phase 1 Study of MRTX1719 in Solid Tumors With MTAP Deletion

Sponsor: Bristol-Myers Squibb

Chicago, IL · +24 more sites

RecruitingPhase 1NCT07241039

A Study to Assess the Adverse Events, Change in Disease Activity, and How Oral ABBV-711 Tablets Move Through the Body as a Monotherapy and in Combination With Intravenously Infused Budigalimab (ABBV-181), in Adults With Advanced Squamous Tumors

Sponsor: AbbVie

Chicago, IL · +5 more sites

RecruitingPhase 3NCT06203210

A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer

Sponsor: Daiichi Sankyo

Chicago, IL · +29 more sites

RecruitingPhase 1 / Phase 2NCT06706076

A Study of BH-30643 in Subjects With Locally Advanced or Metastatic NSCLC Harboring EGFR and/or HER2 Mutations

Sponsor: BlossomHill Therapeutics

Chicago, IL · +23 more sites

RecruitingPhase 1NCT05433142

Study of XmAb®819 in Subjects With Advanced Clear Cell Renal Cell Carcinoma

Sponsor: Xencor, Inc.

Chicago, IL · +18 more sites

RecruitingPhase 1 / Phase 2NCT05098132

Study of STK-012 Alone and With Other Treatments in Patients With Advanced Lung Cancer and Other Cancers

Sponsor: Synthekine

Chicago, IL · +32 more sites

RecruitingPhase 3NCT06686771

Radiotherapy to Block Oligoprogression In Metastatic Non-Small-Cell Lung Cancer

Sponsor: Canadian Cancer Trials Group

Alton, IL · Chicago, IL · Decatur, IL · +68 more sites

RecruitingPhase 1NCT04389632

A Study of Sigvotatug Vedotin in Advanced Solid Tumors

Sponsor: Seagen, a wholly owned subsidiary of Pfizer

Calumet City, IL · Chicago, IL · +103 more sites

RecruitingPhase 1NCT07046923

A Study of LY4175408 in Participants With Advanced Cancer

Sponsor: Eli Lilly and Company

Chicago, IL · +14 more sites

RecruitingPhase 2NCT05742607

IPH5201 and Durvalumab in Patients With Resectable Non-Small Cell Lung Cancer (MATISSE)

Sponsor: Innate Pharma

Chicago, IL · +5 more sites

RecruitingPhase 1NCT05283330

Safety and Tolerability of ²¹²Pb-DOTAM-GRPR1 in Adult Subjects With Recurrent or Metastatic GRPR-expressing Tumors

Sponsor: Orano Med Theranostics, SAS

Chicago, IL · +7 more sites

RecruitingPhase 2NCT05642572

Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)

Sponsor: SWOG Cancer Research Network

Barrington, IL · Bloomington, IL · Canton, IL · +451 more sites

RecruitingPhase 2 / Phase 3NCT03851445

Lung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung Cancer

Sponsor: SWOG Cancer Research Network

Alton, IL · Aurora, IL · +1226 more sites

RecruitingPhase 2 / Phase 3NCT05893888

A Study Evaluating the Safety and Efficacy of PRV111, PRV211, and PRV131 in Subjects With Oral and Lung Cancers

Sponsor: Privo Technologies

Chicago, IL · +3 more sites

RecruitingPhase 2NCT04919382

Temozolomide and Atezolizumab for Subsequent Line for the Treatment of Metastatic or Recurrent Small Cell Lung Cancer

Sponsor: Dwight Owen

Chicago, IL · +4 more sites

RecruitingPhase 2NCT06769126

Using Biomarker Tests to Select and Test New, Personalized Treatments for Extensive Stage Small Cell Lung Cancer, PRISM Study

Sponsor: SWOG Cancer Research Network

Chicago, IL · DeKalb, IL · Geneva, IL · +145 more sites

RecruitingNot applicableNCT05898594

Lung Cancer Screening in High-risk Black Individuals

Sponsor: Massachusetts General Hospital

Chicago, IL · +1 more sites

RecruitingPhase 1NCT06778863

A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation

Sponsor: Clasp Therapeutics, Inc.

Chicago, IL · +20 more sites

RecruitingPhase 2NCT05613413

A Pilot Phase II Study of Maintenance Cabozantinib Plus Pembrolizumab for Patients With Metastatic Squamous Non-Small Cell Lung Cancer (sqNSCLC)

Sponsor: University of Illinois at Chicago

Chicago, IL

RecruitingNot applicableNCT06671613

Evaluating a Fasting-mimicking Diet in Combination With Immunotherapy in Patients With Non-small Cell Lung Cancer

Sponsor: VA Office of Research and Development

Chicago, IL · +3 more sites

RecruitingPhase 1NCT05107674

A Study of NX-1607 in Adults With Advanced Malignancies

Sponsor: Nurix Therapeutics, Inc.

Chicago, IL · +9 more sites

Not yet recruitingPhase 2NCT07871214

A Study to Assess The Safety and Tolerability of Pumitamig-Based Therapy Administered Before Surgery in Participants With Early-Stage Non-Small Cell Lung Cancer (ROSETTA Lung-220)

Sponsor: Bristol-Myers Squibb

Chicago, IL · +8 more sites

Not yet recruitingPhase 1 / Phase 2NCT07707895

DAREON®-36: A Study to Test Obrixtamig in Combination With ZL-1310 in People With Advanced Small Cell Lung Cancer or Other Neuroendocrine Cancers

Sponsor: Boehringer Ingelheim

Chicago, IL · +3 more sites

Listings come from ClinicalTrials.gov and are provided for information only. Always confirm eligibility with the study team and talk with your doctor before making decisions about your care.